Sentry Investment Management LLC Reduces Position in Kenvue Inc. (NYSE:KVUE)

Sentry Investment Management LLC lessened its stake in shares of Kenvue Inc. (NYSE:KVUE) by 14.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,257 shares of the company’s stock after selling 1,181 shares during the quarter. Sentry Investment Management LLC’s holdings in Kenvue were worth $155,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. State Street Corp lifted its stake in Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Kenvue by 8.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after acquiring an additional 7,115,374 shares during the period. Holocene Advisors LP lifted its stake in Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock worth $321,194,000 after acquiring an additional 5,975,392 shares during the period. M&G PLC lifted its stake in Kenvue by 538.0% in the third quarter. M&G PLC now owns 4,341,172 shares of the company’s stock worth $99,847,000 after acquiring an additional 3,660,730 shares during the period. Finally, FMR LLC lifted its stake in Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after acquiring an additional 3,075,019 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of research analyst reports. Canaccord Genuity Group dropped their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group lowered their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Citigroup lowered their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $23.22 on Thursday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The business has a fifty day moving average price of $21.36 and a 200-day moving average price of $22.23. The company has a market capitalization of $44.52 billion, a PE ratio of 43.81, a PEG ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.53%. Kenvue’s payout ratio is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.